Genmab and AbbVie’s bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Tag Archive for: lymphoma
Swiss ADC specialist ADC Therapeutics has reported a statistically positive Phase III result for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma, but a higher rate of fatal adverse events in the experimental arm has overshadowed the efficacy readout and triggered a sharp investor backlash.